Get the Stockscreener App
1.47
6.96%
-0.11
After Hours:
1.49
0.02
+1.36%
Celularity Inc stock is traded at $1.47, with a volume of 68,937.
It is down -6.96% in the last 24 hours and down -12.50% over the past month.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
See More
Previous Close:
$1.58
Open:
$1.53
24h Volume:
68,937
Relative Volume:
0.02
Market Cap:
$42.55M
Revenue:
$26.55M
Net Income/Loss:
$-91.72M
P/E Ratio:
-0.4102
EPS:
-3.584
Net Cash Flow:
$-13.25M
1W Performance:
+8.89%
1M Performance:
-12.50%
6M Performance:
+5.76%
1Y Performance:
-27.94%
1-Day Range:
$1.47
$1.57
1-Week Range:
$1.302
$1.80
52-Week Range:
$0.5601
$2.55
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.47 | 39.95M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Viome CEO Jain to join board of directors at Florham Park-based Celularity - ROI-NJ
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner - Yahoo Finance
Tech innovator Naveen Jain joins Celularity board - The American Bazaar
Celularity Q1 Results: EPS turns positive at $0.02, sales down 66% - scanx.trade
Form 8K Celularity Inc Class A For: 29 September By Investing.com - Investing.com Nigeria
Naveen Jain appointed to Celularity board as Diane Parks resigns - TradingView
Celularity Inc 1Q 2026: Revenue $3.85M, EPS $0.02— 10-Q Summary - TradingView
A profit, but not enough cash for the next 12 months: Celularity (NASDAQ: CELU) says it needs financing. - Stock Titan
Celularity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Celularity Inc. Announces Appointment of Naveen Jain as Director - marketscreener.com
Celularity adds Viome CEO Naveen Jain to board of directors By Investing.com - Investing.com South Africa
Celularity adds Viome CEO Naveen Jain to board of directors - Investing.com
Celularity Announces Naveen Jain to Join Board of Directors - Yahoo Finance
Celularity Inc. (CELU) Total Assets 2025: $107.3M, down 19.1% - Stock Titan
A trust can name two of Celularity's (CELU) five directors under a financing deal. - Stock Titan
Form 8K Celularity Inc For: 28 September By Investing.com - Investing.com Nigeria
Celularity announces $25 million convertible note financing and board changes - Investing.com
Celularity appoints Philip A. Barach to board as Geoffrey Ling resigns - TradingView
Celularity raises USD 10m in first tranche of USD 28m recapitalization - AllSci
Celularity Director Philip Barach Updates Convertible Notes and Warrants, Acquires New Securities - Kalkine Media
Form 4 Celularity Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Celularity Inc For: 25 September - Investing.com India
A note’s share-conversion price fell from $1.66 to $1.50 as a Celularity (CELU) 10% owner bought more notes. - Stock Titan
1,177,000 warrants came with a Celularity (CELU) note purchase by a 10% owner's trust. - Stock Titan
Celularity Secures $10M Initial Financing in Planned $28M Recapitalization - citybiz
Celularity Inc. Announces Appointment of Philip A. Barach to Board - marketscreener.com
Celularity raises over $10M in debt financing, targets cash flow positive by Q1 2027 - Investing.com Nigeria
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements - Investing News Network
Celularity Announces Over $10 Million Initial - Moomoo
CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Drives 4.84% Share GainRevenue Breakdown Analysis - dars.gov.et
Celularity (NASDAQ: CELU) Achieves Nasdaq Compliance for Bid Price and Market Value - kalkinemedia.com
Form 8K Celularity Inc For: 14 September By Investing.com - Investing.com Nigeria
Celularity regains Nasdaq compliance for bid price and market value - Investing.com
Celularity regains Nasdaq compliance for bid price and market value By Investing.com - Investing.com Nigeria
Celularity Regains Nasdaq Compliance on Bid Price and Market Value Rules - Minichart
CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Prevent 6.49% Stock DeclinePerformance Review - dars.gov.et
Celularity (CELU) Stock Slides 8% to $1.54 as Biotech Selling Pressure BuildsFear Greed Index - dars.gov.et
Celularity and MuseCell Innovations Strike New Jersey Manufacturing Deal Worth Up to $300 Million - BioBuzz
Celularity and MuseCell Innovations strike US manufacturing deal with potential $300m upside & 200 jobs - Indian Pharma Post
Celularity Inc (CELUW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Celularity Manufacturing Deal Could Bring $300 Million, 200 Jobs to Florham Park - Morris Focus
Celularity Inc (CELUW) Peer Comparison – Compare with Others - Value Research
Celularity Inc (CELUW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Celularity (CELU) Stock News & Analysis - TechStock²
Celularity shares jump 138.5% after forecasting $300 million MuseCell manufacturing revenue - TechStock²
Celularity Partners with MuseCell Innovations to Manufacture Allogeneic Cell Therapy Products in the US - BioPharm International
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform - Investing News Network
Why Is Celularity Stock Gaining Thursday? - Benzinga
Florham Park Facility at Center of Cell Therapy Manufacturing Deal Worth Up to $300 Million - centraljersey.com
Celularity and MuseCell Innovations announce manufacturing collaboration - ROI-NJ
$Celularity (CELU.US)$ It's 100% happening, guys - Moomoo
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
0.50%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):